| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mariëtte Nederlof, Theo Wj Benschop, Cornelia Adriana de Vries Feyens, Eibert Roelof Heerdin. Clozapine re-exposure after dilated cardiomyopathy. BMJ case reports. vol 2017. 2018-03-28. PMID:28551597. |
a 63-year-old woman with diabetes type ii and a history of breast cancer was treated with clozapine for her refractory schizophrenia. |
2018-03-28 |
2023-08-13 |
Not clear |
| Brian J Lee, Luigi Marchionni, Carrie E Andrews, Alexis L Norris, Leslie G Nucifora, Yeewen Candace Wu, Robert A Wright, Jonathan Pevsner, Christopher A Ross, Russell L Margolis, Akira Sawa, Frederick C Nucifor. Analysis of differential gene expression mediated by clozapine in human postmortem brains. Schizophrenia research. vol 185. 2018-03-26. PMID:28038920. |
our analysis yielded the first comprehensive compendium of genes and pathways differentially expressed upon clozapine treatment in the human brain, which may provide insight into the mechanism and unique efficacy of clozapine, as well as the pathophysiology of schizophrenia. |
2018-03-26 |
2023-08-13 |
human |
| Yan Tang, Marcela Horvitz-Lennon, Walid F Gellad, Judith R Lave, Chung-Chou H Chang, Sharon-Lise Normand, Julie M Donohu. Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program. Psychiatric services (Washington, D.C.). vol 68. issue 6. 2018-03-23. PMID:28196460. |
prescribing of clozapine and antipsychotic polypharmacy for schizophrenia in a large medicaid program. |
2018-03-23 |
2023-08-13 |
Not clear |
| Ivana Goluza, Jay Borchard, Esther Kiarie, Judy Mullan, Nagesh Pa. Exploration of food addiction in people living with schizophrenia. Asian journal of psychiatry. vol 27. 2018-03-20. PMID:28558903. |
outpatients attending a clozapine clinic and possessing a diagnosis of schizophrenia were invited to complete an anonymous survey using the yfas. |
2018-03-20 |
2023-08-13 |
human |
| Arshad A Khan, Asma Ashraf, David Baker, Mohammed S Al-Omary, Lindsay Savage, Avedis Ekmejian, Rajinder Singh Harjit Singh, Stephen Brienesse, Tazeen Majeed, Tracy Gordon, Vincent Drinkwater, Nicholas J Collin. Clozapine and incidence of myocarditis and sudden death - Long term Australian experience. International journal of cardiology. vol 238. 2018-03-19. PMID:28343762. |
clozapine is the cornerstone of therapy for refractory schizophrenia; however, the potential for cardiotoxicity is an important limitation in its use. |
2018-03-19 |
2023-08-13 |
Not clear |
| Adrienne T Gerken, Shunda McGahee, Alex S Keuroghlian, Oliver Freudenreic. Consideration of Clozapine and Gender-Affirming Medical Care for an HIV-Positive Person with Schizophrenia and Fluctuating Gender Identity. Harvard review of psychiatry. vol 24. issue 6. 2018-03-15. PMID:27824636. |
consideration of clozapine and gender-affirming medical care for an hiv-positive person with schizophrenia and fluctuating gender identity. |
2018-03-15 |
2023-08-13 |
Not clear |
| Gabriela Danielski Niehues, Alexandre Balestieri Balan, Vinicius Brum Prá, Raphaela Santos Pellizzaro, Paulo Roberto Antunes da Silva, Manuela Danielski Niehues, Ana Paula Costa, Marcelo Liborio Schwarzbold, Alexandre Paim Dia. Trends in the prescription of clozapine in a psychiatric hospital: a 5-year observational study. Trends in psychiatry and psychotherapy. vol 39. issue 3. 2018-02-28. PMID:28767928. |
clozapine is a well-recognized effective treatment for some patients with treatment-resistant schizophrenia (trs). |
2018-02-28 |
2023-08-13 |
Not clear |
| Myrto Samara, Stefan Leuch. Clozapine in treatment-resistant schizophrenia. The British journal of psychiatry : the journal of mental science. vol 210. issue 4. 2018-02-22. PMID:28373226. |
clozapine in treatment-resistant schizophrenia. |
2018-02-22 |
2023-08-13 |
Not clear |
| Mijeong Kang, Eunkyoung Kim, Thomas E Winkler, George Banis, Yi Liu, Christopher A Kitchen, Deanna L Kelly, Reza Ghodssi, Gregory F Payn. Reliable clinical serum analysis with reusable electrochemical sensor: Toward point-of-care measurement of the antipsychotic medication clozapine. Biosensors & bioelectronics. vol 95. 2018-02-14. PMID:28412661. |
clozapine is one of the most promising medications for managing schizophrenia but it is under-utilized because of the challenges of maintaining serum levels in a safe therapeutic range (1-3μm). |
2018-02-14 |
2023-08-13 |
Not clear |
| Mijeong Kang, Eunkyoung Kim, Thomas E Winkler, George Banis, Yi Liu, Christopher A Kitchen, Deanna L Kelly, Reza Ghodssi, Gregory F Payn. Reliable clinical serum analysis with reusable electrochemical sensor: Toward point-of-care measurement of the antipsychotic medication clozapine. Biosensors & bioelectronics. vol 95. 2018-02-14. PMID:28412661. |
our electrochemical measurements in clinical serum from clozapine-treated and clozapine-untreated schizophrenia groups are well correlated to centralized laboratory analysis for the readily detected uric acid and for the clozapine which is present at 100-fold lower concentration. |
2018-02-14 |
2023-08-13 |
Not clear |
| Mijeong Kang, Eunkyoung Kim, Thomas E Winkler, George Banis, Yi Liu, Christopher A Kitchen, Deanna L Kelly, Reza Ghodssi, Gregory F Payn. Reliable clinical serum analysis with reusable electrochemical sensor: Toward point-of-care measurement of the antipsychotic medication clozapine. Biosensors & bioelectronics. vol 95. 2018-02-14. PMID:28412661. |
this simple and rapid electrochemical approach for serum clozapine measurements should provide clinicians with the timely point-of-care information required to adjust dosages and personalize the management of schizophrenia. |
2018-02-14 |
2023-08-13 |
Not clear |
| Scott Cherry, Dan Siskind, Valeria Spivak, Daniel Wysoczanski, Priyangika Halangod. Fever, confusion, acute kidney injury: is this atypical neuroleptic malignant syndrome following polypharmacy with clozapine and risperidone? Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists. vol 24. issue 6. 2018-02-12. PMID:27194777. |
clozapine is the gold-standard antipsychotic medication for treatment-refractory schizophrenia (trs). |
2018-02-12 |
2023-08-13 |
Not clear |
| Radhika S Joshi, Rolen Quadros, Michael Drumm, Rupasri Ain, Mitradas M Panicke. Sedative effect of Clozapine is a function of 5-HT European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 27. issue 1. 2018-02-12. PMID:27955831. |
sedative effect of clozapine is a function of 5-ht antipsychotic drugs are the mainstay in the treatment of schizophrenia and bipolar disorder. |
2018-02-12 |
2023-08-13 |
Not clear |
| Marina Šagu. Treatment-resistant schizophrenia: challenges and implications for clinical practice. Psychiatria Danubina. vol 27. issue 3. 2018-02-08. PMID:26400145. |
clozapine is recommended as first-line treatment for treatment-resistant schizophrenia (trs) in all guidelines. |
2018-02-08 |
2023-08-13 |
Not clear |
| Jessica L Gören, Adam J Rose, Ryann L Engle, Eric G Smith, Melissa L D Christopher, Nathaniel M Rickles, Todd P Semla, Megan B McCulloug. Organizational Characteristics of Veterans Affairs Clinics With High and Low Utilization of Clozapine. Psychiatric services (Washington, D.C.). vol 67. issue 11. 2018-01-31. PMID:27301765. |
clozapine is the only medication proven effective for treatment-resistant schizophrenia. |
2018-01-31 |
2023-08-13 |
Not clear |
| Jessica L Gören, Adam J Rose, Ryann L Engle, Eric G Smith, Melissa L D Christopher, Nathaniel M Rickles, Todd P Semla, Megan B McCulloug. Organizational Characteristics of Veterans Affairs Clinics With High and Low Utilization of Clozapine. Psychiatric services (Washington, D.C.). vol 67. issue 11. 2018-01-31. PMID:27301765. |
however, in most settings less than 25% of patients with treatment-resistant schizophrenia receive clozapine. |
2018-01-31 |
2023-08-13 |
Not clear |
| Jessica L Gören, Adam J Rose, Eric G Smith, John P Ne. The Business Case for Expanded Clozapine Utilization. Psychiatric services (Washington, D.C.). vol 67. issue 11. 2018-01-31. PMID:27301766. |
in most settings, less than 25% of patients with treatment-resistant schizophrenia receive clozapine, the only medication proven effective for treatment-resistant schizophrenia. |
2018-01-31 |
2023-08-13 |
Not clear |
| Jessica L Gören, Adam J Rose, Eric G Smith, John P Ne. The Business Case for Expanded Clozapine Utilization. Psychiatric services (Washington, D.C.). vol 67. issue 11. 2018-01-31. PMID:27301766. |
therefore, a business case analysis was conducted to assess whether increasing clozapine utilization for treatment-resistant schizophrenia in a health care system would result in direct health care cost savings. |
2018-01-31 |
2023-08-13 |
Not clear |
| Thomas E Winkler, Sarah L Lederer, Eunkyoung Kim, Hadar Ben-Yoav, Deanna L Kelly, Gregory F Payne, Reza Ghodss. Molecular processes in an electrochemical clozapine sensor. Biointerphases. vol 12. issue 2. 2018-01-25. PMID:28460529. |
one example is schizophrenia treatment monitoring of the redox-active antipsychotic clozapine. |
2018-01-25 |
2023-08-13 |
Not clear |
| Matteo Marcatili, Fabio Marsoner, Armando D'Agostino, Thodoris Karnavas, Daniele Bottai, Silvio Scarone, Luciano Cont. Establishment of an induced pluripotent stem cell (iPSC) line from a patient with Clozapine-responder Schizophrenia. Stem cell research. vol 17. issue 3. 2018-01-22. PMID:27934596. |
peripheral blood mononuclear cells (pbmcs) were collected from a patient with treatment-refractory schizophrenia who presented an exceptional clinical response to clozapine. |
2018-01-22 |
2023-08-13 |
Not clear |